Respiratory medicine company Propeller Health stated on Thursday that it has passed the International Organization for Standardization (ISO) 13485:2016 certification for medical device quality management systems,
The ISO certification confirms the company is providing the best quality management systems and regulatory compliance for sensors, apps as well as services.
According to the company, the US FDA-cleared medical devices include sensors that attach to inhalers and mobile apps powered by a robust analytics platform helping patients better manage their asthma and COPD symptoms. The clinician tools are used by providers to help improve care and treatment and strengthen relationship with patients.
ISO is an independent, non-governmental international organisation with a membership of 162 national standards bodies based in Geneva, Switzerland. The 13485:2016 is the latest update to the ISO criteria, which was previously revised in 2003.
To achieve certification, the company spent six months undergoing independent review of the processes, documentation and general culture of quality in accordance with ISO guidelines. The ISO certification builds on the US FDA's quality management system principles and is recognised internationally.
Celltrion's biosimilar EYDENZELT (aflibercept-boav) approved by US FDA
Rigel Pharmaceuticals begins dose expansion phase of R289 study in lower-risk MDS
Precision NeuroMed's glioblastoma multiforme treatment granted FDA Orphan Drug Designation
Merck completes acquisition of Verona Pharma to expand cardio-pulmonary portfolio
Oxford Biomedica expands US operations with acquisition of viral vector facility in North Carolina
DarioHealth and OneStep partner to integrate fall risk technology into digital health platform
Ananda Pharma achieves key Phase 1 milestone for MRX1 CBD program
Alvotech and Advanz Pharma announce EMA acceptance of AVT23 marketing application
Polarean expands Ascend Imaging partnership to boost US market reach
Alto Neuroscience receives FDA Fast Track designation for ALTO-101
Calico Life Sciences' investigational treatment for ADPKD receives US FDA Fast Track Designation